Cost–effectiveness thresholds: pros and cons

Marseille, 2015, Thresholds for the cost–effectiveness of interventions: alternative approaches., Bull World Health Organ, 93, 118, 10.2471/BLT.14.138206

Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001. Available from: http://apps.who.int/iris/bitstream/10665/42435/1/924154550X.pdf [cited 2016 Aug 18].

Garber, 1997, Economic foundations of cost-effectiveness analysis., J Health Econ, 16, 1, 10.1016/S0167-6296(96)00506-1

Shillcutt, 2009, Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules., Pharmacoeconomics, 27, 903, 10.2165/10899580-000000000-00000

Jamison, 2013, Global health 2035: a world converging within a generation., Lancet, 382, 1898, 10.1016/S0140-6736(13)62105-4

Hutubessy, 2003, Generalized cost-effectiveness analysis for national-level priority-setting in the health sector., Cost Eff Resour Alloc, 1, 8, 10.1186/1478-7547-1-8

Global action plan for the prevention and control of noncommunicable diseases 2013-2020. Geneva: World Health Organization; 2013. Available from: http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf [cited 2016 Aug 18].

Hutubessy, 2003, Generalized cost-effectiveness analysis for national-level priority-setting in the health sector., Cost Eff Resour Alloc, 1, 8, 10.1186/1478-7547-1-8

Ranking vaccines: a prioritization framework. Phase I: demonstration of concept and a software blueprint. Washington: National Academies of Sciences, Engineering, and Medicine; 2012. Available from: http://www.nationalacademies.org/hmd/Reports/2012/Ranking-Vaccines-A-Prioritization-Framework-Phase-I.aspx [cited 2016 Mar 15].

Hill, 2000, Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme., JAMA, 283, 2116, 10.1001/jama.283.16.2116

Yong, 2013, The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada., Pharmacoeconomics, 31, 229, 10.1007/s40273-012-0022-5

Hoomans, 2012, Methodological quality of economic evaluations of new pharmaceuticals in the Netherlands., Pharmacoeconomics, 30, 219, 10.2165/11539850-000000000-00000

Oostvogels, 2015, Use of DALYs in economic analyses on interventions for infectious diseases: a systematic review., Epidemiol Infect, 143, 1791, 10.1017/S0950268814001940

Simoens, 2013, Assessment of methodological quality of economic evaluations in belgian drug reimbursement applications., PLoS One, 8, e85411, 10.1371/journal.pone.0085411

Williams, 2015, Lonely at the top and stuck in the middle? The ongoing challenge of using cost-effectiveness information in priority setting. Comment on “Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in Sweden”., Int J Health Policy Manag, 4, 185, 10.15171/ijhpm.2015.32

Zelle, 2013, Cost-effectiveness analysis of breast cancer control interventions in Peru., PLoS One, 8, e82575, 10.1371/journal.pone.0082575

Chhatwal, 2015, Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States., Ann Intern Med, 162, 397, 10.7326/M14-1336

Petta, 2014, Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C., Hepatology, 59, 1692, 10.1002/hep.27010

Linas, 2015, The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection., Ann Intern Med, 162, 619, 10.7326/M14-1313

Meyer-Rath, 2012, The impact and cost of scaling up GeneXpert MTB/RIF in South Africa., PLoS One, 7, e36966, 10.1371/journal.pone.0036966

Creswell, 2014, Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries., BMC Infect Dis, 14, 2, 10.1186/1471-2334-14-2

Guyatt, 2011, GRADE guidelines: 1. Introduction–GRADE evidence profiles and summary of findings tables., J Clin Epidemiol, 64, 383, 10.1016/j.jclinepi.2010.04.026

Schünemann, 2016, GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health., J Clin Epidemiol, S0895-4356(16)00136-0

Norheim, 2014, Guidance on priority setting in health care (GPS-Health): the inclusion of equity criteria not captured by cost-effectiveness analysis., Cost Eff Resour Alloc, 12, 18, 10.1186/1478-7547-12-18

Angelis, 2016, Value-based assessment of new medical technologies: towards a robust methodological framework for the application of multiple criteria decision analysis in the context of health technology assessment., Pharmacoeconomics, 34, 435, 10.1007/s40273-015-0370-z

Ottersen, 2016, A new proposal for priority setting in Norway: open and fair., Health Policy, 120, 246, 10.1016/j.healthpol.2016.01.012

George, 2001, Cost-effectiveness analysis and the consistency of decision making. Evidence from pharmaceutical reimbursement in Australia (1991 to 1996)., Pharmacoeconomics, 19, 1103, 10.2165/00019053-200119110-00004

Harris, 2008, The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004., Med Decis Making, 28, 713, 10.1177/0272989X08315247

Jakubiak-Lasocka, 2014, Cost-effectiveness versus cost-utility analyses: what are the motives behind using each and how do their results differ?—A Polish example., Value Health Reg Issues., 4C, 66, 10.1016/j.vhri.2014.06.008

Iyengar, 2016, Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis., PLoS Med, 13, e1002032, 10.1371/journal.pmed.1002032

Thavorncharoensap, 2013, Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?, Clinicoecon Outcomes Res, 5, 29, 10.2147/CEOR.S38062

Teerawattananon, 2014, The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand., Z Evid Fortbild Qual Gesundhwes, 108, 397, 10.1016/j.zefq.2014.06.017

Youngkong, 2012, Multicriteria decision analysis for including health interventions in the universal health coverage benefit package in Thailand., Value Health, 15, 961, 10.1016/j.jval.2012.06.006

Claxton, 2015, Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients?, Health Econ, 24, 1, 10.1002/hec.3130

Claxton, 2015, Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold., Health Technol Assess, 19, 1, 10.3310/hta19140